IBJNews

Cook wins approval for new stent

Back to TopCommentsE-mailPrintBookmark and Share

Bloomington-based Cook Medical won approval from the U.S. Food and Drug Administration for its drug-coated stent designed to prop open arteries outside the heart and prevent inflammation that might close them again.

The product, called the Zilver PTX Drug-Eluting Stent, already is approved in 50 other markets, including Australia, Japan and Europe. But the United States accounts for roughly 40 percent of the global market in stents for peripheral arteries, so U.S. approval is key for Cook’s revenue from the Zilver product.

Worldwide, peripheral stents had about $2 billion in sales in 2010, according to market research by various firms pulled together by Inspire MD, an Israel-based company developing technologies for coronary and peripheral stents. Industry analysts expect peripheral stents to grow rapidly to about $3.2 billion by the end of next year.

Peripheral artery disease, or PAD, typically occurs in patients’ legs, and is more common in the increasing number of patients suffering from obesity or diabetes. Stents are flexible metal tubes that hold open a section of an artery.

Current treatment options are not ideal. Within a year of diagnosis, as many as 40 percent of U.S. patients end up having an amputation. And according to Cook, 70 percent of patients whose peripheral arteries are propped open through angioplasty see their arteries close again within a year.

Cook’s Zilver stent is coated with the drug paclitaxel—the same as used on many coronary artery stents—which dampens growth of cells in artery walls. The growth can re-close an artery with a stent in it.

In clinical trials, eight of 10 Zilver patients still had their arteries open a year later. Also, half as many Zilver patients needed to come back for a new surgical procedure as did patients receiving a bare metal stent.

“With this approval, treating PAD in the U.S. will begin to undergo the same revolution that drug elution did for treating coronary artery disease,” Dr. Gary Ansel, director of the Center for Critical Limb Care at Riverside Methodist Hospital in Columbus, Ohio, said in a statement released by Cook. “Drug-eluting stents such as Zilver PTX will move quickly, in my opinion, to become the standard of care for PAD patients worldwide.”

The FDA will require Cook to conduct another five-year clinical trial, involving 900 patients, to further monitor safety and efficacy.

While Cook’s is the first drug-coated stent for peripheral arteries to be approved by the FDA, it is likely to see fierce competition.

Minnesota-based Medtronic Inc. has been testing a drug-coated balloon that would prop open arteries, cut down re-closing and yet leave no stent behind.

Also, Illinois-based Abbott Laboratories has been testing its Xpert stent as a treatment for peripheral artery disease.

Still, Rob Lyles, global leader of Cook’s perhperhal intervention division, expressed confidence.

“No other company can match Cook’s commitment to this technology,” he said in a prepared statement, “and by the end of 2013, we expect to have a full suite of drug-eluting peripheral stents in the most commonly used lengths and diameters available to U.S. physicians.”

 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. By Mr. Lee's own admission, he basically ran pro-bono ads on the billboard. Paying advertisers didn't want ads on a controversial, ugly billboard that turned off customers. At least one of Mr. Lee's free advertisers dropped out early because they found that Mr. Lee's advertising was having negative impact. So Mr. Lee is disingenous to say the city now owes him for lost revenue. Mr. Lee quickly realized his monstrosity had a dim future and is trying to get the city to bail him out. And that's why the billboard came down so quickly.

  2. Merchants Square is back. The small strip center to the south of 116th is 100% leased, McAlister’s is doing well in the outlot building. The former O’Charleys is leased but is going through permitting with the State and the town of Carmel. Mac Grill is closing all of their Indy locations (not just Merchants) and this will allow for a new restaurant concept to backfill both of their locations. As for the north side of 116th a new dinner movie theater and brewery is under construction to fill most of the vacancy left by Hobby Lobby and Old Navy.

  3. Yes it does have an ethics commission which enforce the law which prohibits 12 specific items. google it

  4. Thanks for reading and replying. If you want to see the differentiation for research, speaking and consulting, check out the spreadsheet I linked to at the bottom of the post; it is broken out exactly that way. I can only include so much detail in a blog post before it becomes something other than a blog post.

  5. 1. There is no allegation of corruption, Marty, to imply otherwise if false. 2. Is the "State Rule" a law? I suspect not. 3. Is Mr. Woodruff obligated via an employment agreement (contractual obligation) to not work with the engineering firm? 4. In many states a right to earn a living will trump non-competes and other contractual obligations, does Mr. Woodruff's personal right to earn a living trump any contractual obligations that might or might not be out there. 5. Lawyers in state government routinely go work for law firms they were formally working with in their regulatory actions. You can see a steady stream to firms like B&D from state government. It would be interesting for IBJ to do a review of current lawyers and find out how their past decisions affected the law firms clients. Since there is a buffer between regulated company and the regulator working for a law firm technically is not in violation of ethics but you have to wonder if decisions were made in favor of certain firms and quid pro quo jobs resulted. Start with the DOI in this review. Very interesting.

ADVERTISEMENT